What Vyvanse (lisdexamfetamine) dose is equivalent to an adult patient taking Adderall (amphetamine) immediate‑release 30 mg twice daily, given the FDA‑approved maximum daily dose of Adderall IR is 40 mg?

Addressing the FDA Maximum Dose Concern for Adderall IR

You are correct that the FDA-approved maximum daily dose for Adderall IR is 40 mg 1. However, your patient is currently taking 60 mg/day (30 mg twice daily), which exceeds this limit. This creates two critical issues that must be addressed before converting to Vyvanse.

The Current Dosing Problem

Your patient is already on a supra-therapeutic dose of Adderall IR that exceeds FDA recommendations. The guidelines explicitly state that the PDR maximum is 40 mg/day for amphetamines 1. While expert consensus acknowledges that "doses may go higher than the PDR-recommended upper limits on rare occasions," this is not standard practice and the guidelines caution: "If the top recommended dose does not help, more is not necessarily better. A change in drug or environmental or psychosocial intervention may be required" 1.

Recommended Approach to Conversion

Before converting to Vyvanse, you should first attempt to optimize the Adderall IR dose within FDA-approved limits (≤40 mg/day). If the patient requires 60 mg/day for adequate symptom control, this suggests either:

• Poor medication adherence with IR formulation (requiring multiple daily doses)
• Inadequate response to amphetamine therapy at appropriate doses
• Need for adjunctive behavioral interventions
• Possible need for alternative medication class

If Converting to Vyvanse Despite Supra-Therapeutic Baseline:

The maximum FDA-approved dose of Vyvanse is 70 mg/day 2. There is no established conversion ratio between Adderall IR and Vyvanse because:

1. Vyvanse is a prodrug requiring enzymatic conversion to d-amphetamine 3, 4
2. Vyvanse produces lower peak plasma concentrations (Cmax) but similar total exposure (AUC) compared to equivalent doses of immediate-release amphetamine 5
3. The pharmacokinetic profile differs substantially—Vyvanse has delayed Tmax and more gradual onset 5, 6

Practical Conversion Strategy:

Start Vyvanse at 50 mg once daily (the target dose for most adults) 2, regardless of the current Adderall IR dose. This approach is justified because:

• The patient's current 60 mg/day Adderall IR already exceeds recommended limits
• Vyvanse 50-70 mg provides full-day coverage equivalent to multiple IR doses 2, 7
• The prodrug mechanism of Vyvanse provides more sustained therapeutic effect with lower abuse potential 5, 3

Titrate to 70 mg if needed after 1 week, which is the maximum FDA-approved dose 2.

Critical Monitoring Points:

• Do not attempt a direct mg-to-mg conversion—the pharmacokinetics are fundamentally different
• Monitor for both under-treatment (if 50 mg insufficient) and over-treatment (cardiovascular effects, insomnia, appetite suppression)
• Assess blood pressure and pulse at each visit 1
• Re-evaluate the need for such high stimulant doses; consider adding behavioral interventions if symptoms persist 1

Key Caveat:

The fact that your patient requires 60 mg/day of Adderall IR (50% above FDA maximum) is a red flag. This warrants reassessment of the diagnosis, evaluation for comorbid conditions (substance use, mood disorders), assessment of medication adherence, and consideration of whether stimulants are the appropriate treatment. Simply converting to Vyvanse without addressing why the patient needs supra-therapeutic amphetamine doses may perpetuate inadequate treatment 1.